¼¼°èÀÇ ¼Ö¸®¸®½º(Soliris) ÀǾàǰ ½ÃÀå(2025-2035³â)
Global Soliris Drug Market 2025-2035
»óǰÄÚµå : 1811877
¸®¼­Ä¡»ç : Orion Market Research
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 145 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,000 £Ü 5,753,000
Unprintable PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,625 £Ü 9,528,000
Printable PDF & Excel (Corporate License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF & Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼Ö¸®¸®½º ÀǾàǰ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­, À¯Çüº°(Ç÷À屳ȯ, Ç÷ÀåÁÖÀÔ), ¿ëµµº°(¹ßÀÛ¼º ¾ß°£ Ç÷»ö¼Ò´¢Áõ(PNH), ºñÁ¤Çü ¿ëÇ÷¼º ¿äµ¶ ÁõÈıº(aHUS), ÁßÁõ ±Ù¹«·ÂÁõ, ½Ã½Å°æÃ´¼ö¿° ½ºÆåÆ®·³ Àå¾Ö, ±âŸ), ¿¹Ãø ±â°£º° º¸°í¼­(2025-2035³â)

»ê¾÷ °³¿ä

¼Ö¸®¸®½º ÀǾàǰ ½ÃÀåÀº 2024³â 25¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£(2025-2035) µ¿¾È ¿¬Æò±Õ 5.2% ¼ºÀåÇÏ¿© 2035³â¿¡´Â 43¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼Ö¸®¸®½º(¼ººÐ¸í: eculizumab)´Â PNH, aHUS, ÁßÁõ±Ù¹«·ÂÁõ, ½Ã½Å°æÃ´¼ö¿° ½ºÆåÆ®·³ Àå¾Ö µî ¸Å¿ì Èñ±ÍÇÑ ÁúȯÀ» Ä¡·áÇÏ´Â ¾à¹°ÀÔ´Ï´Ù. Èñ±Í À¯Àü¼º Áúȯ¿¡ ´ëÇÑ Àνİú Áø´Ü Áõ°¡°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, ÀÌ ¾à°ú ¿©·¯ À¯ÇüÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ ÀÌ·¯ÇÑ »ý¸íÀ» À§ÇùÇÏ´Â Áúȯ¿¡ ´ëÇÑ À¯ÀÏÇÑ Ä¡·áÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

À¯Àü¼º Áúȯ Áõ°¡·Î ¼Ö¸®¸®½º ¾àǰ ¼ö¿ä Áõ°¡

¼Ö¸®¸®½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇÏ´Â °ÍÀº Àü ¼¼°èÀûÀ¸·Î À¯Àü¼º Áúȯ°ú Èñ±ÍÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, Èñ±ÍÁúȯÀº ÀÏ¹Ý Àα¸ ¾à 2,000¸í Áß 1¸íÀÌ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ÇöÀç Àü ¼¼°èÀûÀ¸·Î 3¾ï ¸í ÀÌ»óÀÌ ¾Î°í ÀÖ´Â Èñ±ÍÁúȯÀº 7,000¿© °³°¡ ³ÑÀ¸¸ç, ±× Áß ¾à 70%°¡ ¼Ò¾Æ±â¿¡ ¹ßº´ÇÕ´Ï´Ù. ¶ÇÇÑ, ¿¬±¸ ¹× Áø´ÜÀ» À§ÇÑ ÀÚ¿øÀº ÇÑÁ¤µÇ¾î ÀÖ°í, Èñ±ÍÁúȯ Ä¡·áÁ¦ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ ¹× ÀçÁ¤Àû Àμ¾Æ¼ºêµµ ÃæºÐÇÏÁö ¾Ê½À´Ï´Ù. Èñ±ÍÁúȯÀÇ 95% ÀÌ»óÀº ¾ÆÁ÷ È¿°úÀûÀÎ Ä¡·á¹ýÀÌ ¾ø¾î ¼Ö¸®¸®½º ±â¹Ý Ä¡·áÁ¦ °³¹ß¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

³ôÀº Ä¡·áºñ¿Í Á¢±Ù¼º ¹®Á¦

¼Ö¸®¸®½º´Â ȯÀÚ 1ÀÎ´ç ¿¬°£ Ä¡·áºñ°¡ 50¸¸ ´Þ·¯°¡ ³Ñ´Â °íºñ¿ëÀ¸·Î ÀÎÇØ ½ÃÀå¿¡¼­ Å« ¾î·Á¿ò¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. 1ȸ Åõ¿© ¹ÙÀÌ¾Ë ´ç ¾à 6,523´Þ·¯·Î ¼Ö¸®¸®½º°¡ ¼¼°è¿¡¼­ °¡Àå ºñ½Ñ ÀǾàǰ Áß Çϳª·Î ²ÅÈü´Ï´Ù. ÀÌ·¯ÇÑ °¡°Ý ¼³Á¤Àº ƯÈ÷ ½ÅÈï ½ÃÀåÀ̳ª ÀÇ·á ¿¹»êÀÌ Á¦ÇÑµÈ Áö¿ª¿¡¼­ Å« ÁøÀÔÀ庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

Áö¿ªº° Àü¸Á

¼¼°èÀÇ ¼Ö¸®¸®½º ÀǾàǰ ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹ ¹× ij³ª´Ù), À¯·´(¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ·¯½Ã¾Æ, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Àεµ, Áß±¹, ÀϺ», Çѱ¹, È£ÁÖ, ´ºÁú·£µå, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«), ±âŸ Áö¿ªÀ¸·Î ºÐ·ùµË´Ï´Ù. ·Î ºÐ·ùµË´Ï´Ù.

ºÏ¹Ì°¡ ¼Ö¸®¸®½º ÀǾàǰ ½ÃÀåÀ» µ¶Á¡ÇÕ´Ï´Ù.

ºÏ¹Ì´Â Àü ¼¼°è ¼Ö¸®¸®½º ÀǾàǰ ½ÃÀå¿¡¼­ °¡Àå Å« ½ÃÀå Á¡À¯À²À» À¯ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº °­·ÂÇÑ ¿¬±¸ ÀÎÇÁ¶ó, ¾çÈ£ÇÑ ±ÔÁ¦ ȯ°æ, ´ë±Ô¸ð Á¤ºÎ ÅõÀÚ, ÁÖ¿ä »ý¸í°øÇÐ ±â¾÷ ¹× Á¦¾àȸ»ç·Î ÀÎÇØ ¼ºÀåÇÏ´Â ¼Ö¸®¸®½º ÀǾàǰ »ýŰ踦 Áö¼ÓÀûÀ¸·Î Áö¹èÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹Ì´Â ¹ßÀÛ¼º ¾ß°£ Ç÷»ö¼Ò´¢Áõ, ºñÁ¤Çü ¿ëÇ÷¼º ¿äµ¶Áõ ÁõÈıº µî Èñ±ÍÁúȯÀÇ À¯º´·üÀÌ ³ô¾Æ ¼Ö¸®¸®½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡´Â °íµµÀÇ Áø´Ü ´É·ÂÀ» Æ÷ÇÔÇÑ ÇコÄÉ¾î ½Ã½ºÅÛÀÌ ±¸ÃàµÇ¾î ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ÁúȯÀÇ Á¶±â ¹ß°ß ¹× Ä¡·á°¡ ¿ëÀÌÇÏ´Ù´Â Á¡ÀÌ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÃÖ±Ù µ¿Çâ

¸ñÂ÷

Á¦1Àå º¸°í¼­ °³¿ä

Á¦2Àå ½ÃÀå °³¿ä¿Í ÀλçÀÌÆ®

Á¦3Àå ½ÃÀå °áÁ¤ ¿äÀÎ

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ¼¼°èÀÇ ¼Ö¸®¸®½º ÀǾàǰ ½ÃÀå : À¯Çüº° ÆÇ¸Å ºÐ¼®

Á¦6Àå ¼¼°èÀÇ ¼Ö¸®¸®½º ÀǾàǰ ½ÃÀå : ¿ëµµº° ÆÇ¸Å ºÐ¼®

Á¦7Àå Áö¿ª ºÐ¼®

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Soliris Drug Market Size, Share & Trends Analysis Report by Type (Plasma Exchange and Plasma Infusion), by Application (Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, and Other), Forecast Period (2025-2035)

Industry Overview

Soliris drug market was valued at $2.5 billion in 2024 and is projected to reach $4.3 billion by 2035, growing at a CAGR of 5.2% during the forecast period (2025-2035). Soliris drug (eculizumab) is the medication to treat very rare diseases such as PNH, aHUS, generalized myasthenia gravis, and Neuromyelitis Optica spectrum disorder. The market is driven by growing awareness and diagnosis of rare genetic diseases, with this drug and a few biosimilars being the only treatments for these life-threatening conditions.

Market Dynamics

Rising Genetic Disorders are Increasing the Demand for Soliris Drug Technology

The demand for Soliris is driven by the increasing prevalence of genetic disorders and rare diseases around the globe. According to the World Health Organization (WHO), a rare disease affects approximately 1 in 2,000 individuals in the general population. Currently, there are over 7,000 known rare diseases impacting more than 300 million people globally, with about 70% of these conditions beginning in childhood. Additionally, there are limited resources for research and diagnosis, as well as insufficient investment and financial incentives for drug development in rare diseases. More than 95% of rare diseases still lack an effective treatment, which further supports the development of therapies based on Soliris.

High Treatment Costs and Access Challenges

Soliris faces significant market challenges due to its high cost, with annual treatment expenses exceeding $500,000 per patient. At approximately $6,523 per single-dose vial, Soliris ranks among the world's most expensive medications. This pricing structure creates substantial access barriers, particularly in emerging markets and regions with limited healthcare budgets.

Market Segmentation

Regional Outlook

The global soliris drug market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Dominates the Soliris Drug Market

North America maintains the largest market share in the global Soliris drug market. The region continues to dominate the growing Soliris drug ecosystem owing to strong research infrastructure, favorable regulatory environments, large government investment, and major biotechnology and pharmaceutical companies. Also, North America has a high prevalence of rare diseases such as Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, driving demand for the Soliris drug. The region has an established healthcare system, including advanced diagnostic capabilities, which facilitates early detection and treatment of these conditions, contributing to market expansion.

Market Players Outlook

The major companies operating in the global Soliris drug market include Alexion Pharmaceuticals, Inc. (now part of AstraZeneca), Amgen Inc., and Samsung Bioepis Co., Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

The Report Covers:

Table of Contents

1. Report Summary

2. Market Overview and Insights

3. Market Determinants

4. Competitive Landscape

5. Global Soliris Drug Market Sales Analysis by Type ($ Million)

6. Global Soliris Drug Market Sales Analysis by Application ($ Million)

7. Regional Analysis

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â